

Lab ID	MVW-8-DME2	Date Specimen Collected	Not Provided
Patient Name	Gilbrough, John	Time Specimen Collected	
Patient ID		Date Received	May 21, 2012 PDT
Date of Birth	Nov. 3, 1952	Date Reported	
Gender	Male	Fax Number	425-354-3545
Ordering Practitioner	Harry N. Dorsey, MD		
Assay	DME Genotype Panel 2 (CYP2C19, CYP2D6 & CYP2C9)		

DRUG METABOLIZING ENZYMES --- GENOTYPE/PHENOTYPE SUMMARY				
GENE PANEL	GENOTYPE DETECTED	normal	PHENOTYPE	EFFECT ON ENZYME FUNCTION
CYP2C19	*1 / *17	*1 / *1	Ultra Rapid Metabolizer	Greater than normal enzyme function.
CYP2D6	*1 / *10	*1 / *1	Intermediate Metabolizer	Relatively modest decrease in enzyme function
CYP2C9	*1 / *2	*1 / *1	Intermediate Metabolizer	Moderate loss of enzyme function. The extent of loss depends not only on genotype, but also the type of drug and on basic pharmacokinetic factors: patient age, sex, body size, kidney function, etc.
VKORC1	A / A	G / G	Poor Metabolizer	Significantly reduced enzyme function.

CYP2C19 enzymes metabolize:		CYP2D6 enzymes metabolize:		CYP2C9 enzymes metabolize:	
<u>PSYCHOTROPICS</u> amitriptyline celexa anafranil valium lexapro rohypnol prozac tofranil manerix zoloft surmontil <u>ANTICONVULSANTS</u> mephenytoin dilantin	<u>PROTON PUMP INHIBITORS</u> nexium prevacid prilosec protonix <u>CARDIOVASCULAR</u> plavix (P) <u>ONCOLOGY</u> cytoxan (P) isophosphamide(P) <u>OTHER</u> soma malarone (P) vfend viracept tolbutamide	<u>PSYCHOTROPICS</u> amphetamines amitriptyline abilify strattera thorazine celexa paxil zoloft effexor cymbalta prozac anafranil norpramin adapin luvox haldol tofranil trilatone	<u>BETA BLOCKERS</u> propranolol toprol coreg lopressor timolol <u>OPIATES</u> hydrocodone(P) lortab (P) vicodin (P) oxycodone percocet tramadol (P) ultram codeine (P) <u>ONCOLOGY</u> tamoxifen (P)	<u>PSYCHOTROPICS</u> prozac zoloft valproic acid <u>NSAIDS</u> celebrex voltaren ibuprofen mobic naproxen feldene <u>HYPOGLYCEMICS</u> chlorpromamide amaryl glyburide starlix avandia orinase	<u>CARDIOVASCULAR</u> cozaar (P) diovan atacand warfarin traclear torsemide les col <u>OTHER</u> luminal dilantin sulfa drugs cannabinoids

NOTE: This specimen was analyzed by PCR following DNA extraction for gene mutations leading to loss or gain of enzyme function. CYP2C9 detects the *2 and *3 variants. VKORC1 is detected simultaneous with CYP2C9 and detects the G>A variant. Because we cannot separate VKORC1 from our CYP2C9 assay, there is no charge and no CPT code applied for reporting this variant. CYP2C19 detects *2, *3, *4, *5, *6, *7, *8 & *17 variants. CYP2D6 detects *2, *3, *4, *5, *6,*7, *8, *9, *10, and *17 (with copy number). The PCR assays were validated pursuant to the 1988 CLIA standards in the Iverson Genetic Diagnostics, Inc. laboratory. The FDA has not cleared or approved some of these tests, nor is FDA premarket review required. The Iverson Genetic Diagnostics laboratory is certified under the Federal 1988 CLIA legislation to perform high complexity clinical laboratory testing and is inspected by the College of American Pathologists. Interpretation and commentary are provided to the practitioner for educational purposes only and should not be taken as diagnostic or treatment recommendations. Diagnosis and treatment decisions are the sole responsibility of the practitioner. For further assistance with the interpretation of these results, please contact Iverson Genetic Diagnostics and ask to speak with Laurance Ferreri, PhD (Laboratory Director) at 425.318.1332.

Test performed by: Iverson Genetic Diagnostics, Inc. 2210 Old Hwy 99, Mount Vernon, Washington 98273

Report Prepared By:

John Gilbrough

Reviewed By:



John Gilbrough



Date: May 23, 2012 PDT

Lab ID	MVW-8-DME2	Date Specimen Collected	Not Provided
Patient Name	Gilbrough, John	Time Specimen Collected	
Patient ID		Date Received	May 21, 2012 PDT
Date of Birth	Nov. 3, 1952	Date Reported	
Gender	Male	Fax Number	425-354-3545
Ordering Practitioner	Harry N. Dorsey, MD		
Assay	DME Genotype Panel 2 (CYP2C19, CYP2D6 & CYP2C9)		

Patient copy:

- As an additional courtesy, we have provided a Patient Wallet Card for you with your pharmacogenetic test results (genes that control drug metabolizing enzymes) to keep with you.
- Please keep this information in your wallet and share with other physicians that may be involved in your care.
- Below are copies of the results that you can cut out and carry in your wallet.
- For additional information --- go to iversongenetics.com and click the "OUR GENETIC TESTS" tab.

 MEDICAL INFORMATION 			
John Gilbrough		Nov 03, 1952	
I have DNA Variations which could affect medication that is prescribed to me			
DRUG METABOLIZING ENZYMES			
GENE PANEL	GENOTYPE DETECTED	<i>normal</i>	PHENOTYPE (TYPE OF METABOLISM)
CYP2C19	*1 / *17	*1 / *1	Ultra Rapid
CYP2D6	*1 / *10	*1 / *1	Intermediate
CYP2C9	*1 / *2	*1 / *1	Intermediate
VKORC1	A / A	G / G	Poor
Iverson Genetic Diagnostics, Inc. 866-900-0903 www.iversongenetics.com			

 MEDICAL INFORMATION 			
John Gilbrough		Nov 03, 1952	
I have DNA Variations which could affect medication that is prescribed to me			
DRUG METABOLIZING ENZYMES			
GENE PANEL	GENOTYPE DETECTED	<i>normal</i>	PHENOTYPE (TYPE OF METABOLISM)
CYP2C19	*1 / *17	*1 / *1	Ultra Rapid
CYP2D6	*1 / *10	*1 / *1	Intermediate
CYP2C9	*1 / *2	*1 / *1	Intermediate
VKORC1	A / A	G / G	Poor
Iverson Genetic Diagnostics, Inc. 866-900-0903 www.iversongenetics.com			